Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 1.06
XOMA's Cash to Debt is ranked lower than
79% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. XOMA: 1.06 )
Ranked among companies with meaningful Cash to Debt only.
XOMA' s 10-Year Cash to Debt Range
Min: 0.01  Med: 1.05 Max: No Debt
Current: 1.06
Equity to Asset -0.51
XOMA's Equity to Asset is ranked lower than
96% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. XOMA: -0.51 )
Ranked among companies with meaningful Equity to Asset only.
XOMA' s 10-Year Equity to Asset Range
Min: -0.77  Med: 0.01 Max: 0.82
Current: -0.51
-0.77
0.82
F-Score: 1
Z-Score: -28.80
M-Score: -4.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -574.94
XOMA's Operating margin (%) is ranked lower than
73% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. XOMA: -574.94 )
Ranked among companies with meaningful Operating margin (%) only.
XOMA' s 10-Year Operating margin (%) Range
Min: -2191.67  Med: -180.30 Max: 13.17
Current: -574.94
-2191.67
13.17
Net-margin (%) -457.91
XOMA's Net-margin (%) is ranked lower than
72% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. XOMA: -457.91 )
Ranked among companies with meaningful Net-margin (%) only.
XOMA' s 10-Year Net-margin (%) Range
Min: -2153.94  Med: -203.70 Max: 14.89
Current: -457.91
-2153.94
14.89
ROA (%) -86.28
XOMA's ROA (%) is ranked lower than
81% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. XOMA: -86.28 )
Ranked among companies with meaningful ROA (%) only.
XOMA' s 10-Year ROA (%) Range
Min: -139.63  Med: -59.54 Max: 4.68
Current: -86.28
-139.63
4.68
ROC (Joel Greenblatt) (%) -1248.15
XOMA's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. XOMA: -1248.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XOMA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1636.29  Med: -236.98 Max: 46.51
Current: -1248.15
-1636.29
46.51
Revenue Growth (3Y)(%) -55.70
XOMA's Revenue Growth (3Y)(%) is ranked lower than
84% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. XOMA: -55.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
XOMA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -60.9  Med: -21.30 Max: 147.7
Current: -55.7
-60.9
147.7
EBITDA Growth (3Y)(%) -29.20
XOMA's EBITDA Growth (3Y)(%) is ranked lower than
80% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. XOMA: -29.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
XOMA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -39.7  Med: -20.10 Max: 31.1
Current: -29.2
-39.7
31.1
EPS Growth (3Y)(%) -29.80
XOMA's EPS Growth (3Y)(%) is ranked lower than
78% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. XOMA: -29.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
XOMA' s 10-Year EPS Growth (3Y)(%) Range
Min: -53  Med: -11.60 Max: 36.5
Current: -29.8
-53
36.5
» XOMA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

XOMA Guru Trades in Q1 2014

John Burbank 49,774 sh (New)
Louis Moore Bacon 75,000 sh (New)
Paul Tudor Jones 33,233 sh (+62.71%)
» More
Q2 2014

XOMA Guru Trades in Q2 2014

Louis Moore Bacon 75,000 sh (unchged)
John Burbank Sold Out
Paul Tudor Jones Sold Out
» More
Q3 2014

XOMA Guru Trades in Q3 2014

Louis Moore Bacon Sold Out
» More
Q2 2015

XOMA Guru Trades in Q2 2015

Jim Simons 665,511 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with XOMA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 6.17
XOMA's P/S is ranked higher than
61% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. XOMA: 6.17 )
Ranked among companies with meaningful P/S only.
XOMA' s 10-Year P/S Range
Min: 0.55  Med: 6.01 Max: 63.23
Current: 6.17
0.55
63.23
Current Ratio 1.88
XOMA's Current Ratio is ranked lower than
75% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. XOMA: 1.88 )
Ranked among companies with meaningful Current Ratio only.
XOMA' s 10-Year Current Ratio Range
Min: 0.63  Med: 3.04 Max: 6.65
Current: 1.88
0.63
6.65
Quick Ratio 1.88
XOMA's Quick Ratio is ranked lower than
70% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. XOMA: 1.88 )
Ranked among companies with meaningful Quick Ratio only.
XOMA' s 10-Year Quick Ratio Range
Min: 0.63  Med: 3.04 Max: 6.65
Current: 1.88
0.63
6.65
Days Sales Outstanding 65.89
XOMA's Days Sales Outstanding is ranked lower than
53% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. XOMA: 65.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
XOMA' s 10-Year Days Sales Outstanding Range
Min: 7.93  Med: 77.46 Max: 882.08
Current: 65.89
7.93
882.08

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.08
XOMA's Price/Median PS Value is ranked lower than
57% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. XOMA: 1.08 )
Ranked among companies with meaningful Price/Median PS Value only.
XOMA' s 10-Year Price/Median PS Value Range
Min: 0.1  Med: 2.20 Max: 69.99
Current: 1.08
0.1
69.99
Earnings Yield (Greenblatt) (%) -70.47
XOMA's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. XOMA: -70.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XOMA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -70.47  Med: 16.30 Max: 21.8
Current: -70.47
-70.47
21.8

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 13 17 41 149
EPS($) -0.59 -0.44 -0.34 0.31
EPS without NRI($) -0.59 -0.44 -0.34 0.31

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:X0M.Germany,
XOMA Corp was incorporated in Delaware in 1981 and became a Bermuda-exempted company in December 1998. The Company discovers and develops antibody-based therapeutics. Several of its antibodies have properties due to their interaction at allosteric sites on specific protein rather than the orthosteric, or active sites. The compounds are designed to either enhance or diminish the protein's activity as desired. Its lead product candidate, gevokizumab, is a proprietary potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). It is also developing XOMA 3AB, a combination, or cocktail, of antibodies designed to neutralize the most potent of botulinum toxins. Its geographic segments include United States, Europe, and Asia Pacific. The Company's competitors include AbbVie Inc., Biovitrum AB, Allergan, Novartis AG, pSivida, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Emergent BioSolutions, Inc. In addition to regulations in the United States, the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of any future products.
» More Articles for XOMA

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Xoma Corporation of Pendency of Cl Jul 30 2015 
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 
comment on XOMA Mar 06 2013 
XOMA Ltd. Reports Operating Results (10-K) Mar 10 2011 
XOMA Ltd. Reports Operating Results (10-K/A) Dec 27 2010 
XOMA Ltd. Reports Operating Results (10-Q/A) Nov 12 2010 
XOMA Ltd. Reports Operating Results (10-Q) May 06 2010 
XOMA Ltd. Reports Operating Results (10-Q) Aug 06 2009 
XOMA Ltd. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Xoma... Sep 03 2015
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Xoma... Aug 26 2015
XOMA CORP Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors... Aug 25 2015
XOMA CORP Financials Aug 22 2015
Law Offices of Marc S. Henzel Announces Securities Class Action Periods Aug 20 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Xoma Corporation of Pendency of... Aug 19 2015
TRADING ALERT: The Rosen Law Firm Reminds Xoma Corporation Investors of Important Deadline in Class... Aug 18 2015
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of... Aug 14 2015
Guidance & Quarterly Review on Four Biotech Companies Aug 14 2015
10-Q for XOMA Corp. Aug 12 2015
XOMA CORP Files SEC form 10-Q, Quarterly Report Aug 10 2015
Leaner Xoma looks to switch gears — again Aug 10 2015
Edited Transcript of XOMA earnings conference call or presentation 6-Aug-15 8:30pm GMT Aug 07 2015
XOMA to Present at the 2015 Wedbush PacGrow Healthcare Conference Aug 07 2015
Xoma reports 2Q loss Aug 06 2015
Xoma reports 2Q loss Aug 06 2015
XOMA Corp Earnings Call scheduled for 4:30 pm ET today Aug 06 2015
XOMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 06 2015
XOMA Reports Financial Results for Second Quarter 2015 Aug 06 2015
Q2 2015 XOMA Corp Earnings Release - After Market Close Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK